BCA
GALT icon

Benchmark Capital Advisors’s Galectin Therapeutics GALT Stock Holding History

Benchmark Capital Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$764K Hold
222,700
– – 0.76% 42
2018
Q3 		$1.34M Buy
222,700
+1,000
+0.5% +$5.5K 1.01% 31
2018
Q2 		$1.41M Hold
221,700
– – 1.07% 30
2018
Q1 		$1.05M Buy
221,700
+36,500
+20% +$170K 0.83% 41
2017
Q4 		$619K Sell
185,200
-9,000
-5% -$22.8K 0.48% 56
2017
Q3 		$416K Hold
194,200
– – 0.32% 79
2017
Q2 		$478K Hold
194,200
– – 0.38% 66
2017
Q1 		$447K Sell
194,200
-4,000
-2% -$6.03K 0.35% 69
2016
Q4 		$194K Buy
198,200
+80,000
+68% +$71.1K 0.16% 108
2016
Q3 		$134K Buy
118,200
+58,600
+98% +$104K 0.1% 117
2016
Q2 		$88K Hold
59,600
– – 0.07% 120
2016
Q1 		$85K Hold
59,600
– – 0.07% 114
2015
Q4 		$98K Sell
59,600
-10,000
-14% -$22.9K 0.08% 115
2015
Q3 		$163K Sell
69,600
-2,000
-3% -$4.72K 0.13% 113
2015
Q2 		$195K Sell
71,600
-28,000
-28% -$84.4K 0.14% 115
2015
Q1 		$334K Sell
99,600
-500
-0.5% -$1.79K 0.22% 89
2014
Q4 		$347K Sell
100,100
-33,550
-25% -$148K 0.23% 86
2014
Q3 		$672K Buy
133,650
+44,650
+50% +$348K 0.46% 62
2014
Q2 		$1.23M Buy
89,000
+4,000
+5% +$49.8K 0.77% 49
2014
Q1 		$1.3M Hold
85,000
– – 0.9% 39
2013
Q4 		$687K Buy
85,000
+19,500
+30% +$180K 0.48% 65
2013
Q3 		$653K Buy
65,500
+45,500
+228% +$307K 0.47% 69
2013
Q2 		$85K Buy
+20,000
New +$81.9K 0.07% 124

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Benchmark Capital Advisors's GALT Position: Q4 2018 in Review

Benchmark Capital Advisors held its Galectin Therapeutics (GALT) position steady in Q4 2018 at 222,700 shares worth $764K. The position accounts for 0.76% of the portfolio, ranked #42.

Benchmark Capital Advisors first reported a position in GALT in Q2 2013 and has held it in 23 quarters since. The position peaked at $1.41M in Q2 2018. 61 funds tracked by Wall St. Rank hold GALT as of Q4 2018.

  • Benchmark Capital Advisors held 222,700 shares of Galectin Therapeutics worth $764K as of Q4 2018.
  • Benchmark Capital Advisors left its Galectin Therapeutics share count unchanged in Q4 2018.
  • Galectin Therapeutics made up 0.76% of Benchmark Capital Advisors's portfolio in Q4 2018, its #42 holding.
  • Benchmark Capital Advisors first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 23 quarters since.
  • Benchmark Capital Advisors's Galectin Therapeutics position peaked at $1.41M in Q2 2018.
  • 61 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2018.

Based on Benchmark Capital Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.